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Abstract
Serotonin 5-HT2A receptor is widely distributed in the central nervous system and plays an 
important role in sensorimotor function, emotion regulation, motivation, executive control, 
learning and memory. We investigated its role in rat maternal behavior, a naturalistic behavior 
encompassing many psychological functions that the 5-HT2A receptor is involved in. We first 
showed that activation of 5-HT2A receptor by TCB-2 (a highly selective 5-HT2A agonist, 1, 2.5 or 
5.0 mg/kg) disrupted maternal behavior dose-dependently, and this effect was reduced by 
pretreatment with a 5-HT2A receptor antagonist MDL 100907, but exacerbated by pretreatment 
with a 5-HT2C receptor antagonist SB242084 and a 5-HT2C receptor agonist MK212, indicating 
that the maternal disruptive effect of 5-HT2A activation is receptor-specific and can be modulated 
by 5-HT2C receptor bidirectionally. We then microinjected TCB-2 into two brain regions 
important for the normal expression of maternal behavior: the medial prefrontal cortex (mPFC) 
and the medial preoptic area (mPOA) and found that only acute intra-mPFC infusion of TCB-2 
suppressed pup retrieval, whereas intra-mPOA had no effect. Finally, using c-Fos 
immunohistochemistry, we identified that the ventral bed nucleus of stria terminalis (vBNST), the 
central amygdala (CeA), and the dorsal raphe (DR) were additionally involved in the maternal-
disruptive effect of TCB-2. These findings suggest that the 5-HT2A receptor in the mPFC and 
other maternally related regions is required for the normal expression of maternal behavior 
through its intrinsic action or interactions with other receptors (e.g. 5-HT2C). Functional disruption 
of this neuroreceptor system might contribute to postpartum mental disorders (e.g. depression and 
psychosis) that impair the quality of maternal care.
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1. Introduction
The 5-HT2A receptor is densely expressed in various cortical areas (e.g. prefrontal cortex, 
piriform and enthorinal cortex) and subcortical areas, such as basal ganglia (e.g. caudate 
nucleus and accumbens) and the limbic system (Pompeiano et al., 1994). It plays an 
important role in a wide range of psychological functions, from sensorimotor function, 
emotion regulation, motivation, learning and memory to executive control (Zhang and 
Stackman, 2015). Dysfunctions of this receptor system have been suggested to contribute to 
several major neuropsychiatric disorders, such as schizophrenia, major depression, autism 
and Alzheimer’s disease (Aznar and Hervig Mel, 2016; Fakhoury, 2016). Overall, the 5-
HT2A receptor appears to be an important neuromodulatory system that has a broad impact 
on basic brain functions.
Maternal behavior in rats is a naturally expressed and highly motivated behavior with its 
onset and maintenance critically dependent on many psychological functions that the 5-
HT2A receptor is intimately involved in. In addition, the 5-HT2A receptor system and various 
sex hormones (e.g. estrogen, prolactin) that are fundamentally important for maternal 
behavior show various reciprocal interactions (Fink et al., 1996; Liang and Pan, 2000). Thus, 
it is logic to think that this receptor system should play a role in maternal behavior. This idea 
also fits well with the observation that the 5-HT2A receptor is found in the brain regions 
important for olfactory processing (e.g. piriform and enthorinal cortex, endopiriform 
nucleus, and olfactory bulb/anterior olfactory nucleus), an important function necessary for 
maternal behavior. Surprisingly, at this time, there is no direct evidence supporting a role of 
5-HT2A receptor in the regulation of rat maternal behavior. The only available evidence is 
that drugs with a certain antagonist and agonist action on 5-HT2A receptor, such as clozapine 
or DOI (2,5-dimethoxy-4-iodoamphetamine), respectively, disrupt maternal behavior upon 
acute treatment (Li et al., 2004; Zhao and Li, 2009a, b, 2012). However, because both 
clozapine and DOI also have an action on 5-HT2C receptor, and activation of 5-HT2C alone 
is able to cause a severe disruption of maternal behavior care (Chen et al., 2014; Wu et al., 
2016), it can be said that the maternal-disruptive effect of clozapine and DOI is due to their 
actions on 5-HT2C receptor alone. Furthermore, recent work shows that selective blockade 
of 5-HT2A receptor alone is ineffective to alter maternal care (Chen et al., 2014), casting a 
doubt on the involvement of the 5-HT2A receptor in maternal behavior.
Because activation of 5-HT2A receptor is capable of facilitating dopamine cell activity and 
dopamine release (Bortolozzi et al., 2003), and this action of dopamine is known to mediate 
rat maternal behavior, especially maternal motivation (Afonso et al., 2007; Febo et al., 2010; 
Li and Fleming, 2003a; Numan, 2007), it is possible that activation of 5-HT2A receptor, 
instead of blocking it, may cause alteration of maternal behavior. The present study tested 
this idea and examined the neurobiological mechanisms underlying the 5-HT2A receptor 
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effect in maternal behavior. We also explored the potential interactive effect of 5-HT2A and 
5-HT2C receptors in maternal behavior in light of the findings that both 5-HT2A and 5-HT2C 
receptors are expressed throughout the mesolimbic and corticostriatal circuits (Bubar et al., 
2011) and they often play opposing roles in various brain functions and psychological 
processes relevant to rat maternal behavior. Our findings revealed that the 5-HT2A receptor, 
especially that expressed in the mPFC, is required for the normal expression of maternal 
behavior through its intrinsic action and/or interactions with other receptors (e.g. 5-HT2C) or 
other neurotransmitter systems, such as dopamine. This work is scientifically significant as it 
enhances our understanding of the basic neurochemical basis of maternal behavior. It is also 
clinically significant, as it implies that dysregulation of frontal 5-HT2A receptors may 
contribute to impaired maternal care as observed in people with postpartum depression who 
show elevated cortical 5-HT2A receptor binding (Bhagwagar et al., 2006). Because many of 
these patients are treated with selective serotonin reuptake inhibitors (SSRIs), and chronic 
SSRI treatment could induce an up-regulation of the 5-HT2A receptors (Hamon and Blier, 
2013; Massou et al., 1997), this study also sheds light on the potential long-term negative 
impact of SSRI use during lactation on the quality of maternal care.
2.1 Materials and methods
2.1. Animals
Naïve pregnant female Sprague-Dawley rats (gestational days 6 upon arrival to the animal 
facility) were purchased from Charles River Inc. All rats were housed individually in 48.3 
cm × 26.7 cm × 20.3 cm transparent polycarbonate cages under 12-h light/dark conditions 
(lights on at 6:30 am), and had access to standard laboratory rat chow and tap water ad 
libitum. The colony was maintained with a controlled temperature (21 ± 1 °C) and a relative 
humidity of 45–60%. Experiments were conducted during the light cycle. All animal 
manipulations were reviewed and approved by the University of Nebraska Institutional 
Animal Care and Use Committee, and were carried out in compliance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals.
2.2. Drugs and choices of dosage
TCB-2 (4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl) methylamine hydrobromide) was 
used as the main pharmacological tool to investigate the role of the 5-HT2A receptor in 
maternal behavior. It is highly selective on 5-HT2A receptors, with no reported actions on 
other receptors (McLean et al., 2006). TCB-2, MK212 [6-Chloro-2-(l-piperazinyl) pyrazine 
hydrochloride] and SB242084 [6-Chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-
pyridinyl)oxy]-3-pyridiny]-1H-indole-1-carboxyamide dihydrochloride hydrate] were 
obtained from Tocris Bioscience (Ellisville, MO, USA). MDL100907 [(R)-(+)-a-(2,3-
dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol] was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). TCB-2 and MK212 was dissolved in 0.9% saline, 
while MDL100907 was dissolved in a minimal amount (up to 1%) glacial acetic acid and 
made up to volume with 0.9% saline. SB242084 was dissolved in 0.9% saline solution 
containing 8% hydroxypropyl-β-cyclodex-trin and 25 mM citric acid. All drugs were 
administrated subcutaneously except in Experiment 4 (an intracranial infusion). Doses of 
TCB-2, MDL100907, MK212, and SB242084 were chosen either based on our previous 
Gao et al. Page 3
Neuropharmacology. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
study (Chen et al., 2014) or several recent reports (Boulougouris et al., 2008; Burghardt et 
al., 2007; Fox et al., 2009; Strong et al., 2009). In Experiment 4, the bilateral microinjection 
(0.5 μl at 0.5μl/min) started 1 min after the insertion of the injector, which remained in place 
for an additional 1 min before removal to allow for drug diffusion.
2.3. Basic procedure of the maternal behavior test
The basic procedure was identical to what has been described in our previous studies (Chen 
et al., 2014; Zhao and Li, 2009b). Starting 2 or 3 days prior to the first possible expected 
parturition date, the subjects were monitored in the morning and afternoon for signs of 
parturition. Once the dam was found with pups in the morning (that day was designated as 
postpartum day 1, PPD 1) or in the afternoon (PPD 0), two shredded paper towels were 
provided for nesting materials. On PPD 2, each litter was culled to 8 pups (4 males and 4 
females with the most visible milk bands) and all subjects were changed to clean observation 
cages with their litters.
On the maternal behavior test days, pups were first removed from the dam and the nest was 
destroyed. Ten seconds later, the pups were placed back in the cage at the corner diagonal to 
the original nest site or dam sleeping corner. Each test was recorded by video cameras and 
analyzed manually using a computer with an event-recording program (JWatcher, http://
www.jwatcher.ucla.edu). The raters were blind to each dam’s treatment condition. The 
following behaviors were recorded and analyzed: pup retrieval (a rat picking up a pup in her 
mouth and carrying it back to the nest site), hovering over pup (a rat positioning herself over 
the pups with legs splayed to accommodate the pups, including hover, high and low 
crouching-over posture), pup licking (a rat placing its tongue on the anogenital area and the 
rest of a pup’s body), nest building (a rat picking up nest material in her mouth and 
transporting it back to the nest site or pushing the material with her forepaws towards the 
nest site). The first pup retrieval latency was defined as the time elapsed from the first pup 
approach to the retrieval of the first pup into the nest. 600s was assigned to non-responders 
who did not approach or retrieve the testing pups. After the test, unretrieved pups were 
returned to the nest site. On PPD 2 or 3, to screen for baseline maternal performance and 
habituate dams to the testing procedure, we did a pup retrieval test (removing pups then 
return them 10 s later) for 10 min, and at the end of the 10-min period, unretrieved pups 
were returned to the nest site. Only those that retrieved all 8 pups were used in the 
subsequent tests. Rats were typically tested at several time points before (−30 min) and after 
the drug administration (e.g. 30 min, 90 min). Frequency and/or duration of various maternal 
responses were recorded for 10 min.
2.4. Experiment 1: basic effects of 5-HT2A activation by TCB-2 on maternal behavior
In this experiment, we tested 8 postpartum rats using a within-subjects Latin square design 
to determine whether 5-HT2A receptor is involved in the regulation of maternal behavior 
expression and establish a minimum effective dose of TCB-2. Mother rats were randomly 
assigned to receive either vehicle (VEH), or one of the three doses of TCB-2 (5-HT2A 
agonist, 1.0, 2.5 or 5.0 mg/kg, sc) on PPD 4, 6, 8, and 10. Maternal behavior was tested for 
10 min at 30 min before and 30 min, 120 min, 24 h after the injection. Each rat was tested 
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across the four treatment conditions, thus it served as its own control. Various measures of 
maternal behavior were recorded and quantified (e.g. frequency or duration).
2.5. Experiment 2: receptor specificity of TCB-2’s maternal disruptive effect
This experiment was aimed to examine the receptor specificity of 5-HT2A receptor and 
confirm TCB-2’s effects on maternal behavior in Experiment 1 using a between-subjects 
design, since maternal behavior is known to decline with the progress of lactation. TCB-2 
(2.5 mg/kg) was tested together with MDL100907 (a 5-HT2A antagonist, 1.0, 2.0 mg/kg, sc) 
or saline. Specifically, on PPD 4, 6, 8, and 10, 32 mother rats (n = 8 per group) were 
randomly assigned to receive either a double injection of VEH (saline with 1% glacial acetic 
acid)+VEH (saline, n = 8), VEH (1% acid saline)+TCB-2 (n = 8), MDL100907-1.0+TCB-2 
(n = 8), MDL100907- 2.0+TCB-2 (n = 8). The first VEH or MDL100907 was injected 10 
min before the second VEH or TCB-2 injection. Maternal behavior was tested for 10 min at 
30 min before, 30 min, 90 min and 150 min after TCB-2 injection.
2.6. Experiment 3: interactions between 5-HT2A receptor and 5-HT2C receptor on maternal 
behavior
The 5-HT2A and 5-HT2C receptors often has opposing effects on behavior (Popova and 
Amstislavskaya, 2002; Robinson et al., 2008; Winstanley et al., 2004). In this experiment, 
we examined how the maternal disruptive effect of TCB-2 is altered by the blockade or 
activation of 5-HT2C receptor in an attempt to elucidate the possible interaction between 
these two serotonin receptors on maternal behavior. TCB-2 (2.5 mg/kg) was tested together 
with either SB242084 (a 5-HT2C antagonist, 0.6 and 1.0 mg/kg, sc,), or MK212 (a 5-HT2C 
agonist, 0.5, 1.0 mg/kg, sc). It should be noted that at the tested doses, SB242084 has no 
effect on maternal care (unpublished observations), whereas MK212 disrupts maternal 
behavior (Chen et al., 2014; Wu et al., 2016). On PPD 4, 6, 8, and 10, 29 mother rats (n = 7–
8 per group) were randomly assigned to receive either SB242084-0.6+TCB-2 (n = 8), 
SB242084-1.0+TCB-2 (n = 7), MK212-0.5+TCB-2 (n = 7), or MK212-1.0+TCB-2 (n = 7), 
and their data were compared with those of the VEH+VEH (n = 8) and VEH+TCB-2 (n = 8) 
groups from Experiment 2. On each test day, the first VEH or SB242084 was injected at 10 
min before the second VEH or TCB-2 injection, while MK212 was injected together with 
TCB-2 based on our previous studies showing that MK212’s time course of action on 
maternal behavior is similar to that of TCB-2 (around 2 h) (Chen et al., 2014; Wu et al., 
2016). Maternal behavior was tested for 10 min at 30 min before, 30 min, 90 min and 150 
min after TCB-2 injection on PPD 4, 6, 8, and 10.
2.7. Experiment 4: neural basis of TCB-2’s effect on maternal behavior: a microinjection 
study
In this study, we attempted to identify the brain regions where TCB-2 acts to disrupt 
maternal behavior by centrally infusing TCB-2 into the mPOA or mPFC. We chose the 
mPOA because it is the most critically important brain region for maternal behavior 
(Numan, 2007). We chose the mPFC because it is not only involved in maternal behavior 
(Afonso et al., 2007; Febo et al., 2010; Zhao and Li, 2012), but also appears to mediate the 
behavioral and neurochemical effects of 5-HT2A activation (Feng et al., 2015; Kuroki et al., 
2003). On day 11–13 of gestation, rats were anaesthetized using a mixture of ketamine HCl 
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(90 mg/kg) and xylazine (4 mg/kg) (ip), and implanted with bilateral stainless-steel guide 
cannulas (22 gauge; Plastics One, Inc.) into the mPOA (n = 5) or mPFC (n = 26). The 
incisor bar was set at −3.4 mm. For the mPOA cannulation, the coordinates were set as: AP 
−0.5 mm, ML ± 0.75 mm, DV −6.5 mm (Small et al., 2003). For the mPFC, the coordinates 
were: AP + 3.0 mm, ML ± 0.75 mm, DV −2.2 mm (Febo et al., 2010).
In the mPOA experiment, we did a quick screening test on 5 postpartum females. They were 
tested for 10 min at 10 and 60 min after the central infusion of VEH, 0.1, 0.4, or 4.0 μg/side/
0.5μl/side of TCB-2 on PPD 4, 6, 8, and 10, respectively. In the mPFC experiment, two 
batches of rats were tested. The first batch of 8 rats were tested identically as those in the 
mPOA experiment under the same dose range (VEH, 0.1, 0.4, or 4.0 μg/side/0.5μl/side). 
Based on the results from that study, we then used a between-subjects design and tested 
another batch of 18 rats randomly assigned to either the VEH (n = 8) or TCB-2 (n = 10) 
groups. Rats were tested for 10 min at 30 and 120 min after the central infusion of VEH or 
TCB-2 4.0 μg/side/0.5μl/side for 4 days on every other day from PPD 4 to 10. At the end of 
behavioral tests, rats were sacrificed and perfused. Their brains were sectioned and then 
stained with cresyl violet before viewing cannula placement as previously reported (Feng et 
al., 2015). The location of the injection site was mapped onto a stereotaxic atlas (Paxinos, 
2005) (Figure 4A).
2.8. Experiment 5: neural basis of TCB-2 effect on maternal behavior: a c-Fos 
immunohistochemistry study
To broaden our search of the relevant brain regions involved in the mediation of TCB-2’s 
maternal disruptive effect, we used c-fos immunohistochemistry and examined the increased 
c-fos expressions in acute and repeated TCB-2-treated rats. A total of 46 postpartum rats 
were randomly divided into one of six groups: 5-day VEH (n = 10), 5-day 2.5 mg/kg TCB-2 
(n = 9) and 5.0 mg/kg TCB-2 (n = 10) groups, as well as 1-day VEH (n = 6), 1-day 2.5 
mg/kg TCB-2 (n = 6) and 5.0 mg/kg TCB-2 (n = 5) groups. For the 5-day groups, maternal 
behavior was tested for 10 min once daily from PPD 6 to 9 starting at 30 min after TCB-2 or 
vehicle injection. For the 1-day groups, maternal behavior was tested once daily from PPD 6 
to 9, but no injection was done.
On PPD 10, all rats received either TCB-2 or VEH injection. One hour later, rats were 
overdosed and perfused as described in our previous work and their brains were extracted for 
c-Fos immunoreactivity staining (Zhao and Li, 2010, 2012). The number of positive cells 
characterized by clearly labeled nuclei was counted unilaterally in six serial sections with 
comparable anatomical levels across the treatment groups. We focused on the mPFC, 
nucleus accumbens shell (NAs) and nucleus accumbens core (NAc), dorsolateral striatum 
(DLSt), ventral lateral septum (LSv), mPOA, ventral tegmental area (VTA), and dorsa raphe 
(DR), because 5-HT2A/2C receptor agonist (DOI) and antagonist (clozapine and olanzapine) 
are shown to have effects on these regions in mother rats (Zhao and Li, 2010, 2012). DR was 
also chosen because it is a major serotonergic brain site (Azmitiz and Segal, 1978; Liu et al,. 
2000; Queree et al., 2009; Steinbusch, 1981). Other brain regions analyzed included the 
ventral bed nuclsus of the stria terminalis (vBNST), central (CeA) and medial amygdala 
(MeA), dentate gyrus (DG), and periaqueductal gray (PAG) (Paxinos, 2005).
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2.9. Statistical analysis
Statistical analyses were performed using SPSS 20 software (SPSS Inc., Chicago, IL, USA). 
Maternal behavior data from each test day (PPD 4, 6, 8 and 10) were analyzed separately 
using a factorial repeated measures analysis of variance (ANOVA), with group as the 
between-subjects factor and test time point as the within-subjects factor. Group differences 
at different test time points were further investigated using simple main effect tests (one-way 
ANOVA) followed by LSD post hoc tests for multiple comparisons when necessary. Data 
from the experiments with a Latin square or within-subjects design were analyzed using the 
Paired-Sample test. In Experiment 5, repeated measures ANOVAs were conducted to 
examine the effects of repeated TCB-2 administration from PPD 6 to 9. c-Fos data were 
analyzed using multivariate analysis of variance in a 2×2 design (drug and treatment 
condition as between-subjects factors, brain regions as within-subjects factors), and 
significant effects were followed up using the LSD post hoc test comparing the within-
treatment condition across drug, and within-drug condition across treatment. Because the 
latency was not normally distributed, those data were analyzed using nonparametric 
Kruskal-Wallis test, and Mann-Whitney U test if the overall significant effects were 
determined. All data are presented as mean ± SEM. Differences were considered statistically 
significant if p < 0.05. In Experiment 3, 1 rat in the SB242084-1.0+TCB-2 group died 
unexpectedly before PPD 10, thus its data on that day were not included. Except for the data 
from Experiment 1, we only presented pup retrieval as a representation of the maternal 
disruptive effect of TCB-2 for simplicity reason. All other data (i.e. hovering over pup, 
licking and nest building) from Experiments 2, 3 and 4 are included in the supplementary 
materials.
3. Results
3.1. Experiment 1: basic effects of 5-HT2A activation by TCB-2 on maternal behavior
Acute TCB-2 treatment dose-dependently disrupted various maternal responses. In 
comparison to the VEH-treated rats, rats under the influence of TCB-2 retrieved fewer pups 
into the nest at the 30 min (p = 0.047, 0.006, and 0.011 for TCB-2 1.0, 2.5, and 5.0 mg/kg) 
and 120 min time points (p = 0.033, 0.003, and 0.000 for TCB-2 1.0, 2.5, and 5.0 mg/kg) 
(Figure 1A). This disruption disappeared at the 24 h time point (p > 0.17). In addition, 
TCB-2 dose-dependently prolonged the 1st pup retrieval latency, decreased amount of time 
spent on hovering over pup and nest building at the 30 min and 120 min points (all p <0.05) 
(Figure 1B, 1C and 1E). It also suppressed pup licking at the 120 min point (p = 0.034 and 
0.050, for TCB-2 1.0 and 5.0 mg/kg respectively).
3.2. Experiment 2: receptor specificity of TCB-2’s disruptive effect on maternal behavior
Once again, acute treatment of TCB-2 severely disrupted various components of maternal 
behavior on PPD 4. This confirmed the TCB-2’s disruptive effect on maternal behaviors in 
Experiment 1 using the within-subjects design. As expected, pretreatment of the 5-HT2A 
antagonist MDL100907 dose-dependently attenuated the TCB-2-induced maternal 
disruption. Figure 2 shows the results of TCB-2 treatment alone, and MDL100907 (1.0 or 
2.0 mg/kg) + TCB-2 treatment on pup retrieval at four test time points on PPD 4 in 
comparison to the vehicle control (data from PPD 6, 8 10 are similar to those from PPD 4. 
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For simplicity, they are not presented). Both doses of MDL100907 were effective in 
reversing the effect of TCB-2 and 1.0 mg/kg dosage appears to be even more effective. 
Repeated measures ANOVA revealed a main effect of group [F(3, 28) = 6.557, p = 0.002], a 
main effect of test time [F(3, 84) = 17.014, p = 0.000], and a significant group × test time 
interaction [F(9, 84) = 2.842, p = 0.006]. Post hoc LSD tests indicated that the VEH+TCB-2 
and MDL100907-2.0+TCB-2 groups retrieved fewer pups than the VEH+VEH group (p < 
0.001 and p = 0.004, respectively), while the MDL100907-1.0+TCB-2 group actually 
retrieved more pups than the VEH+TCB-2 group (p = 0.029).
3.3. Experiment 3: interactions between 5-HT2A receptor and 5-HT2C receptor on maternal 
behavior
TCB-2-induced pup retrieval disruption was worsened by MK212 and SB242084 treatment, 
which activates and blocks 5-HT2C receptor, respectively. Figure 3A shows the pretreatment 
effect of SB242084 (0.6 and 1.0 mg/kg) on PPD 4. Repeated measures ANOVA revealed a 
main effect of group [F(3, 27) = 45.633, p = 0.000], a main effect of test time [F(3, 81) = 
100.785, p = 0.000], and a significant group × test time interaction [F(9, 81) = 12.813, p = 
0.000]. Post hoc LSD tests indicated that the two SB242084+TCB-2 groups retrieved fewer 
pups than the VEH+TCB-2 group (p = 0.026 and 0.009, respectively).
Figure 3B shows the results of pretreatment with MK212 (0.5, 1.0 mg/kg) treatment on pup 
retrieval at four test time points on PPD 4. Repeated measures ANOVA revealed a main 
effect of group [F(3, 26) = 37.187, p = 0.000], a main effect of test time [F(3, 78) = 52.172, 
p = 0.000], and a significant group × test time interaction [F(9, 78) = 6.457, p = 0.000]. Post 
hoc LSD tests indicated that the VEH+TCB-2, MK212-0.5+TCB-2, and MK212-1.0+TCB-2 
groups retrieved fewer pups than the VEH+VEH group (all p < 0.001). More importantly, 
the MK212-1.0+TCB-2 group retrieved fewer pups than the VEH+TCB-2 group (p = 0.005).
3.4. Experiment 4: neural basis of TCB-2’s effect on maternal behavior: a microinjection 
study
To examine the neuroanatomical basis of action of TCB-2 in maternal behavior, we 
microinjected TCB-2 at 0.1, 0.4, or 4 μg/side into the mPOA or mPFC. All the injection sites 
were verified in the intended targeted areas. Results showed that intra-mPOA infusion of 
TCB-2 had no effect on pup retrieval (all p > 0.241) (Figure 4B). However, intra-mPFC 
infusion of TCB-2 at 4 μg/side, but not at 0.1 or 0.4 μg/side, decreased the number of pups 
retrieved at 60 min time point (p = 0.008; Figure 4C). This result from a within-subjects 
study was confirmed in the subsequent study with a between-subjects design. TCB-2 at 4 μg/
side infused into the mPFC transiently suppressed pup retrieval at 30 min (p = 0.006) but not 
120 min (p = 0.144) time points on PPD 4 (Figure 4D). Such a disruption was also observed 
on PPD 6, 8, and 10, but the magnitude was reduced so that the group difference was found 
to be not significant (all p > 0.051), indicating a tolerance-like effect with TCB-2-induced 
activation of prefrontal 5-HT2A receptor.
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3.5. Experiment 5: neural basis of TCB-2 effect on maternal behavior: a c-Fos 
immunohistochemistry study
Behaviorally, acute TCB-2 treatment on PPD 6 dose-dependently reduced the number of 
pups retrieved (p < 0.05). With repeated administration, TCB-2 gradually lost its disruption 
in a dose-dependent fashion (VEH vs. TCB-2 2.5, p > 0.05 on PP 7, 8, and 9; VEH vs. 
TCB-2 5.0, p < 0.001 on PP 7 and 8; p > 0.05 on PPD 9) (Figure 5A). Repeated measures 
ANOVA revealed a significant main effect of drug treatment [F (2, 26) = 18.629, p < 0.001], 
test day [F (3, 78) = 11.152, p < 0.001] and interaction between the two factors [F (6, 78) = 
3.076, p = 0.009].
With the acute treatment, TCB-2 significantly altered c-Fos immunoreactivity in the vBNST 
[F (2, 14) = 5.463, p = 0.018], CeA [F (2, 14) = 6.634, p = 0.009] and DR [F (2, 14) = 4.902, 
p = 0.024], with no significant change in other examined regions (all p > 0.05). Specifically, 
in comparison to the VEH treatment, TCB-2 at 5.0 mg/kg significantly increased c-Fos 
immunoreactivity in the vBNST, CeA and DR (all p < 0.05), whereas TCB-2 at 2.5 mg/kg 
increased c-Fos immunoreactivity only in the vBNST and DR (all p < 0.05), showing a dose-
dependent effect in the CeA (Figure 5B and D). The two TCB-2 groups did not differ from 
each other. With the repeated TCB-2 treatment, TCB-2 failed to alter c-Fos 
immunoreactivity in the regions where acute TCB-2 had an effect, including the vBNST [F 
(2, 18) = 0.093, p > 0.05], CeA [F (2, 18) = 2.005, p > 0.05] and DR [F (2, 18) = 0.625, p > 
0.05], and also failed to show c-Fos immunoreactivity in other examined areas (Figure 5C). 
The lack of change in c-Fos immunoreactivity matches well with the lack of behavioral 
effects of repeated TCB-2 treatment, indicating that the c-Fos signal is valid in revealing 
brain regions targeted by TCB-2.
4. Discussion
This is the first study to provide direct evidence that 5-HT2A is critically important for the 
regulation of maternal behavior in rats. Behaviorally, activation of the 5-HT2A receptor by 
TCB-2 dose-dependently disrupted various maternal responses, especially pup retrieval and 
hovering over pups. Neurochemically, we showed that the effect of TCB-2 was receptor-
specific, as only pretreatment of a selective 5-HT2A receptor antagonist MDL100907 
reduced the maternal disruptive effect of TCB-2, while pretreatment with 5-HT2C receptor 
drugs, SB242084 (a 5-HT2C antagonist) or MK212 (a 5-HT2C agonist), exacerbated it. This 
result also suggests that the maternal disruptive effect of 5-HT2A activation is modulated by 
5-HT2C receptor bidirectionally. Central action of TCB-2 points out that the 5-HT2A 
receptors, especially those in the mPFC, vBNST, CeA and DR, are likely involved in the 
mediation of maternal behavior. The 5-HT2A receptors in the mPOA did not appear to be 
involved in the effect of TCB-2, as results from both the microinjection and c-fos studies did 
not find any effect when the MPOA was manipulated or examined. However, this conclusion 
needs to be further examined because of the small size.
Maternal behavior is a cluster of observable behavioral responses (e.g. pup retrieval, pup 
licking, nursing and nest building) organized seamlessly to ensure the survival of the young. 
Various psychological processes such as sensorimotor function, attention, emotional 
processing, incentive motivation, and memory, are involved in the support of these 
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behavioral responses. In light of the current findings, one obvious question is: how does 
TCB-2 affect basic psychological processes to cause maternal disruption? Our recent work 
suggests that the TCB-2’s induced disruption is not likely caused by the drug’s effect on 
mothers’ motivational and emotional processing of the incentive salience of pups, as dams 
treated with TCB-2 actually increased their preference to pups over a male conspecific in a 
pup preference test (Wu et al., under review). This enhanced emotional and motivational 
responses towards pups might be due to the stimulating effect of TCB-2 on dopamine 
neurotransmission in the mesocortical and mesolimbic dopamine systems (Di Giovanni et 
al., 2000; Di Matteo et al., 2002). TCB-2 also does not appear to cause a disruption of 
maternal behavior by simply increasing motor activity and stereotypical behaviors. However, 
previous work suggests that just increasing locomotor behavior and stereotypies in rats does 
not significantly alter their ability to be maternal (Johns et al., 1998). Also in a related study, 
we did not find any significant change in motor activity in dams treated with TCB-2 (Wu et 
al., under review). One possible mechanism may involve the action of TCB-2 on behavioral 
organization, as stimulation of 5-HT2A receptor is shown to increase impulsive response 
while suppression of 5-HT2A receptor decrease it (Winstanley et al., 2004). Similar to DOI, 
a selective 5-HT2A/2C agonist which we have shown to exert a disruptive effect on rat 
maternal behavior via its action on 5-HT2A receptor (Zhao and Li, 2010), TCB-2, like other 
5-HT2A agonists (Gonzalez-Maeso et al., 2007; Krebs-Thomson et al., 1998), is a 
hallucinogen (e.g. inducing head twitches) (Fox et al., 2009) that could disrupt the 
organization of behavioral response patterns (e.g. increased fragmentation and premature, or 
‘impulsive’ responding) necessary for the normal expression of maternal responses. In other 
words, TCB-2 might have disrupted the behavioral organization aspect of the executive 
function. In our tests, we did observe that rats treated with TCB-2 often exhibited interrupted 
normal sequence of pup-directed responses (e.g. pup retrieval and pup licking, 
fragmentation), indicating a disruption of the organization of microregulatory maternal 
responses. This idea is also consistent with our later finding that the mPFC is one critical site 
for the action of TCB-2 (Figure 5), and the mPFC is known for its role in the executive 
control (Chudasama, 2011). Future work needs to employ other highly selective 5-HT2A 
receptor agonists, coupled with detailed behavioral analysis of specific executive functions 
to further test this hypothesis.
Our previous work fails to show any maternal effect with blockade of 5-HT2A receptor, as 
acute and repeated treatment of MDL100907 does not alter maternal behavior at the 
behaviorally active doses (Chen et al., 2014). In the present study, MDL100907 pretreatment 
attenuated the maternal disruptive effect of TCB-2, confirming that the mechanism of action 
of TCB-2 is through stimulation of 5-HT2A receptor. A more interesting and unexpected 
finding is that both 5-HT2C agonist and antagonist potentiated the maternal disruptive effect 
of TCB-2. Although the 5-HT2A and the 5-HT2C receptors are closely related members of 
the G-protein-coupled receptors that share the highest degree of sequence homology (about 
50% overall sequence identity) and cellular signaling pathways (Becamel et al., 2004), they 
often play opposing roles in various brain functions and psychological processes. Overall 
evidence seems to suggest that activation of 5-HT2A receptors has a similar function to 
blockade of 5-HT2C receptors, whereas activation of 5-HT2C receptors is functionally 
equivalent to blockade of 5-HT2A receptors. These opposing effects between 5-HT2A and 5-
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HT2C receptors are found in the modulation of dopamine release and cell firing (Di Giovanni 
et al., 2002; Di Matteo et al., 2002; Ichikawa et al., 2001; Millan et al., 1998), in behavioral 
inhibition and impulsivity (Robinson et al., 2008; Winstanley et al., 2004), reversal learning 
(Boulougouris et al., 2008), head-twitch response (Vickers et al., 2001), sexual behavior 
(Popova and Amstislavskaya, 2002), as well as in drug-motivated behaviors (Filip et al., 
2004; McMahon et al., 2001). Based on these observations, we originally expected to see the 
5-HT2C antagonist SB240084 to enhance while the 5-HT2C agonist MK212 to reverse the 
maternal disruptive effect of TCB-2. Indeed, the behavioral enhancement effect of 
SB240084 was confirmed. SB 240084 may do so to further increase TCB-2-induced 
dopamine release in the mPFC and NA and cell firing in the ventral tegmental area, causing 
disruption of behavioral organization (fragmentation) (Di Giovanni et al., 2002; Di Matteo et 
al., 2002; Ichikawa et al., 2001; Millan et al., 1998). In contrast, MK212, as a 5-HT2C 
agonist, was supposed to counteract the TCB-2-induced increase in dopamine release (Di 
Giovanni et al., 2000; Di Matteo et al., 2002) to reduce the maternal disruptive effect of 
TCB-2. The lack of such an effect is important, as it indicates that TCB-2 could disrupt 
maternal behavior through other mechanisms, such as by influencing the glutamatergic 
function in the mPFC, in addition to its known impacts on the VTA dopaminergic cells. Our 
microinjection work showing that intra-mPFC injection of TCB-2 suppressed pup retrieval, 
is consistent with this idea. This idea is also supported by the observation that the mPFC 
glutamatergic neurons do express 5-HT2A (Nocjar et al., 2015); lesions of the mPFC can 
cause pup retrieval deficits (Afonso et al., 2007); and inactivation or inhibition of neuronal 
activity in the mPFC disrupt maternal behavior (Febo et al., 2010).
The direct interaction between the 5-HT2A and 5-HT2C in the mPFC has been reported in 
motor impulsivity (Anastasio et al., 2015). Existing evidence suggests that the mPFC 
glutamatergic neurons predominantly express 5-HT2A, whereas the mPFC GABAergic 
interneurons predominantly express 5-HT2C (Nocjar et al., 2015). Therefore, TCB-2 could 
stimulate the 5-HT2A receptors on the glutamatergic neurons to disrupt maternal behavior, 
while MK 212 could stimulate the 5-HT2C receptors on the GABAergic interneurons to 
cause a disinhibition of mPFC glutamatergic neurons, leading to a further exacerbation of 
maternal disruption. This is an intriguing idea and worth further investigation.
Our previous c-Fos studies show that the 5-HT2A/2C agonist DOI and antagonists clozapine 
and olanzapine, though not selective to 5-HT2C receptors, increased c-Fos expression in the 
mPFC (Zhao and Li, 2010, 2012). In the present study, although we did observe an increase 
in c- Fos expression in the mPFC by acute TCB-2, the effect did not reach a statistically 
significant level. The c-Fos results reveal several other brain sites where TCB-2 might have 
an action, including the vBNST, CeA and DR, all of which has been implicated in the 
regulation of certain aspect of maternal behavior (Barofsky et al., 1983; Bosch et al., 2010; 
Numan and Numan, 1995). The serotonergic neurons in the DR project to the VTA and 
NAc, where both 5-HT2A and 5-HT2C receptors have been found. Thus, the DR may 
regulate maternal motivation toward the young (Bridges, 2015). The CeA appears to be a 
crucial component for normal activation of maternal aggression circuitry and was shown to 
mediate the suppression of maternal care (Dulac et al., 2014). It has been shown that 
maternal aggression was increased after microinjection of the 5-HT2A/2C receptor agonist α-
Methyl-5-hydroxytryptamine maleate into the amygdala (de Almeida et al., 2006). In 
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addition, lesion of vBNST disrupts maternal behavior, especially pup retrieval (Numan and 
Numan, 1996), and maternal expression is associated with increased c-Fos expression and 
increased binding to arginine vasopressin V1a and oxytocin receptors in the BNST (Bosch et 
al., 2010; Numan and Numan, 1995).
The present work has implications for our thinking about the effects of antidepressant (e.g. 
SSRIs) use on maternal care in depressed mothers which consist of approximately 10–20% 
of all mothers (Gjerdingen and Yawn, 2007; Susser et al., 2016), and more than 40% of 
depressed mothers are prescribed with antidepressants (Lind et al., 2017). On the one hand, 
SSRI treatment reduces depressive symptoms and improve certain functions needed for 
adequate maternal care, such as the overall functioning and maternal role functioning (e.g. 
gratification in the maternal role) (Logsdon et al., 2009; Logsdon et al., 2011). Thus, SSRI 
use is beneficial for improving maternal care. On the other hand, chronic SSRI treatment is 
known to induce an up-regulation of the 5-HT2A receptors in the frontal cortex (Hamon and 
Blier, 2013; Massou et al., 1997). As our findings indicate that enhanced frontal 5-HT2A 
receptors might be detrimental to maternal behavior, chronic SSRI treatment itself might 
cause a negative impact on the quality of maternal care. Animal research using postpartum 
depression models are important in untangling the effects of depression and SSRI treatment 
on maternal behavior.
Taken together, the 5-HT2A receptor plays an important role in the modulation of maternal 
behavior in rats. We suggest three neural systems where 5-HT2A receptors may achieve this 
effect. First, the 5-HT2A receptors in the VTA and NAc may modulate the neuronal activity 
of dopamine neurons and dopamine release to affect incentive aspects of maternal care (Li 
and Fleming, 2003b; Numan, 2007). Second, the 5-HT2A receptors in the mPFC could 
modulate the glutamatergic and GABAergic neurotransmission and regulate impulsivity and 
motivation. Finally, the 5-HT2A receptors in the vBNST, CeA and DR may interact with 
other subcortical structures (e.g. medial preoptic area) to alter maternal behavior. Clinically, 
our finding that the 5-HT2A receptor is critically important for maternal behavior in rats may 
have revealed that one possible cause of postpartum mental disorders (e.g. depression and 
psychosis) is the functional disruption of this receptor system (Guiard and Di Giovanni, 
2015; Messa et al., 2003). This idea is supported by the observations that one mechanism of 
major depression and the antidepressant action of selective serotonin reuptake inhibitors 
(SSRIs) are mediated by the 5-HT2A receptors (Hamon and Blier, 2013). Future research 
needs to be conducted to elucidate the exact central mechanisms of 5-HT2A receptor in 
maternal behavior. This research will shed light on the possible functional dysregulation of 
the 5-HT2A receptor in postpartum mental disorders. Such knowledge may help inform the 
development of effective interventions to promote and facilitate maternal care.
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Highlights
1. Activation of 5-HT2A receptor by TCB-2 disrupts maternal behavior
2. MDL100907 dose-dependently reduces TCB-2-induced maternal disruption
3. Either SB242084 or MK212 exacerbates TCB-2-induced maternal disruption
4. Acute intra-mPFC infusion of TCB-2 suppresses pup retrieval
5. Acute but not repeated TCB-2 alters c-Fos expression in the vBNST, CeA, 
and DR
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Figure 1. 
Effects of systemic TCB-2 injection on maternal behavior. Mother rats were randomly 
assigned to receive an injection of vehicle (VEH), or TCB-2 (1.0, 2.5 or 5.0 mg/kg, sc) on 
PPD 4, 6, 8 and 10 when maternal behavior was observed for 10 min at 4 time points: 30 
min before, 30 min, 120 min and 24 h after the injection. Data are presented and expressed 
as mean + SEM. A, number of pup retrieved; B, latency of first pup retrieved; C, duration of 
hovering over pups; D, duration of pup licking; E, duration of nest building. * p < 0.05, ** p 
< 0.01, *** p < 0.001, significantly different between the different drug administrations 
(VEH vs. TCB-2).
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Figure 2. 
Effects of MDL100907 (1.0, 2.0 mg/kg) pretreatment on TCB-2 (2.5 mg/kg)’s disruptive 
effect on pup retrieval. On PPD 4, the first VEH and MDL100907 was injected 10 min 
before the second VEH and TCB-2 injection. Pup retrieval was tested for 10 min at 30 min 
before (baseline), 30 min, 90 min and 150 min after TCB-2 injection. Number of pups 
retrieved in each test is expressed as mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 
significantly different between the VEH+VEH and +TCB-2 groups. # p < 0.05 significantly 
different between MDL100907-(1.0 or 2.0)+TCB-2 and VEH+TCB-2 groups.
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Figure 3. 
Effects of SB242084 (0.6, 1.0 mg/kg) (A) and MK212 (0.5, 1.0 mg/kg) (B) pretreatment on 
TCB-2 (2.5 mg/kg)’s disruptive effect on pup retrieval. SB242084 (0.6, 1.0 mg/kg) was 
injected 10 min before the second VEH and TCB-2 injection, while MK212 (0.5, 1.0 mg/kg) 
was injected together with TCB-2. Pup retrieval was tested for 10 min at 30 min before 
(baseline), 30 min, 90 min and 150 min after TCB-2 injection. Number of pups retrieved in 
each test is expressed as mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 significantly 
different between the VEH+VEH and TCB-2 groups. # p < 0.05, ## p < 0.01 significantly 
different between SB242084-(0.6 or 1.0)+TCB-2 or MK212-(0.5, or 1.0) and VEH+TCB-2 
groups.
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Figure 4. 
(A) Histological representations of microinjection sites and schematic diagrams showing the 
location of the injector tips in the mPOA and mPFC. Data are reconstructed from Paxinos 
and Watson (Paxinos, 2005). Numbers to the left of the sections indicate anteroposterior 
distance from bregma in millimeters. The arrow in the histological representation section 
and black dot in the schematic diagrams denotes the infusion placement. Effects of TCB-2 
microinfused into the medial preoptic area (mPOA, B), or medial prefrontal cortex (mPFC, 
C and D) on pup retrieval throughout the four test days (PPD 4, 6, 8 and 10). Number of pup 
retrieval in each test is expressed as mean + SEM. * p < 0.05 significantly different between 
the VEH and TCB-2 groups.
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Figure 5. 
(A) Effects of repeated TCB-2 administration on pup retrieval. Maternal behavior was tested 
for 10 min once daily from PP 6 to 9, starting at 30 min after the injection. Number of pups 
retrieved is expressed as mean + SEM. * p < 0.05, ** p < 0.01, significantly different 
between the VEH and TCB-2. # p < 0.05, ## p < 0.01 significantly different between the two 
TCB-2 groups. Effects of acute (B) and repeated TCB-2 administration (C) on c-Fos 
immunoreactivity. On PP 10, 1 h after the drug injection, all rats were overdosed and 
perfused and their brains were extracted for c-Fos immunoreactivity staining. Number of c-
Fos positive cells is expressed as mean + SEM. * p < 0.05, ** p < 0.01, significantly 
different between the VEH and TCB-2. vBNST, the ventral bed nucleus of the stria 
terminalis; CeA, central amygdala; DR, dorsal raphe. (D), Brain atlas diagrams depict the 
region viewed in the representative images of these brain regions, and c-Fos staining 
photomicrographs in these regions. Distance from Bregma in the rostrocaudal planes is 
indicated. (1–3), acute VEH; (4–6), acute TCB-2, 2.5mg/kg; (7–9), acute TCB-2 5.0mg/kg. 
Scale bar = 100 um.
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1. Experiment 2: receptor specificity of TCB-2’s disruptive effect on maternal behavior 
As expected, pretreatment of the 5-HT2A antagonist MDL100907 dose-dependently 
attenuated the certain aspect of TCB-2-induced maternal disruption. Figure S.1 shows the results 
of TCB-2 treatment alone, and MDL100907 (1.0 or 2.0 mg/kg)+TCB-2 treatment on various 
maternal responses at four test time points on PPD 4 in comparison to the vehicle control (data 
from PPD 6, 8 10 are similar to those from PPD 4. For simplicity, they are not presented). Both 
doses of MDL100907 were effective in reversing the effect of TCB-2 and 1.0 mg/kg dosage 
appears to be even more effective.  
Figure S.1A shows that TCB-2 prolonged the 1st pup retrieval latency, and MDL100907 was 
effective in reversing the effect of TCB-2. Mann-Whitney U test indicated that the VEH+TCB-2 
and MDL100907-(1.0, or 2.0)+TCB-2 groups had a significantly longer latency of 1st pup retrieval 
than the VEH+VEH group (all p <0.046). More importantly, the MDL100907-1.0+TCB-2 group 
actually had a shorter latency than the VEH+TCB-2 group (p = 0.033) at 90 min time point. 
Figure S.1B shows the results of hovering over pups. TCB-2 decreased amount of time spent 
on hovering over pups. Repeated measures ANOVA revealed a main effect of group [F(3, 28) = 
8.772, p = 0.000], a main effect of test time [F(3, 84) = 4.577, p = 0.005], but not a significant 
group × test time interaction [F(9, 84) = 1.285, p = 0.257]. Post hoc LSD tests indicated that the 
VEH+TCB-2 and MDL100907-(1.0 or 2.0 mg/kg)+TCB-2 groups spent less time on hovering 
over pups than the VEH+VEH group (all p < 0.021). MDL100907 were not effective in reversing 
the effect of TCB-2 (both p > 0.107), although the MDL100907-1.0+TCB-2 group was not 
significant different from VEH+VEH group (p = 0.103) at 90 min time point.  
Figure S.1C shows the results of pup licking. Repeated measures ANOVA revealed a main 
effect of group [F(3, 28) = 3.134, p = 0.041], a significant group × test time interaction [F(9, 84) 
= 3.389, p = 0.001], but not a main effect of test time [F(3, 84) = 2.386, p = 0.075]. Post hoc LSD 
tests indicated that the MDL100907-(1.0 or 2.0 mg/kg)+TCB-2 groups (both p < 0.043) but not 
the VEH+TCB-2 group (p = 0.153) spent less time on pup licking than the VEH+VEH group.  
Figure S.1D shows the results of nest building. TCB-2 decreased amount of time spent on 
nest building, and both doses of MDL100907 were effective in reversing the effect of TCB-2. 
Repeated measures ANOVA revealed a main effect of group [F(3, 28) = 7.825, p = 0.001], a main 
effect of test time [F(3, 84) = 9.974, p = 0.000], but not a significant group × test time interaction 
[F(9, 84) = 1.510, p = 0.158]. Post hoc LSD tests indicated that VEH+TCB-2 group (p = 0.002) 
but not the MDL100907-(1.0 or 2.0 mg/kg)+TCB-2 groups (both p > 0.264) spent less time on 
nest building than the VEH+VEH group, while the MDL100907-(1.0 or 2.0 mg/kg)+TCB-2 
groups actually spent more time on nest building than the VEH+TCB-2 group (p = 0.001, 0.000, 
respectively).  
 Figure S.1. Effects of MDL100907 (1.0, 2.0 mg/kg) pretreatment on TCB-2 (2.5 mg/kg)’s 
disruptive effect on maternal behavior. Latency of 1st pup retrieval (A), and time spent on hovering 
over pups (B), nursing (C) and nest-building (D) on PPD 4 are presented. On PPD 4, the first VEH 
and MDL100907 was injected 10 min before the second VEH and TCB-2 injection. Maternal 
behavior was tested for 10 min at 30 min before (baseline), 30 min, 90 min and 150 min after TCB-
2 injection. Data are expressed as mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 significantly 
different between the VEH+VEH and (VEH or MDL100907)+TCB-2 groups. # p < 0.05, ## p < 
0.01 significantly different between MDL100907-(1.0 or 2.0)+TCB-2 and VEH+TCB-2 groups. 
 2. Experiment 3: interactions between 5-HT2A receptor and 5-HT2C receptor on maternal 
behavior 
TCB-2-induced maternal disruption was worsened by MK212 and SB242084 treatment, 
which activates and blocks 5-HT2C receptor, respectively. Figures S.2 and S.3 show the 
pretreatment effect of SB242084 (0.6 and 1.0 mg/kg) or MK212 (0.5, 1.0 mg/kg) on various 
maternal responses at four test time points on PPD 4. 
Figure S.2A shows the results of the 1st pup retrieval latency. TCB-2 prolonged the 1st pup 
retrieval latency, and neither doses of SB242084 were effective in enhancing the effect of TCB-2. 
Kruskal-Wallis test showed a significant group difference at baseline, 30, 90, and 150 min time 
points (all p <0.023). Mann-Whitney U test indicated that VEH+TCB-2 and two SB242084+TCB-
2 groups had a significantly longer latency of the 1st pup retrieval than the VEH+VEH group (all 
p <0.005). The SB242084-(0.6 or 1.0)+TCB-2 groups were not significantly different from the 
VEH+TCB-2 group (all p > 0.063) at all 30, 90, and 150 min time points. 
Figure S.2B shows the results of hovering over pups. TCB-2 decreased amount of time spent 
on hovering over pups, and SB242084 were effective in enhancing the effect of TCB-2. Repeated 
measures ANOVA revealed a main effect of group [F(3, 27) = 22.818, p = 0.000], a main effect 
of test time [F(3, 81) = 14.969, p = 0.000], and a significant group × test time interaction [F(9, 81) 
= 2.112, p = 0.038]. Post hoc LSD tests indicated that the VEH+TCB-2, SB242084-(0.6 or 
1.0)+TCB-2 groups spent less time on hovering over pups than the VEH+VEH group (all p < 
0.001), and the SB242084-(0.6 or 1.0)+TCB-2 groups spent less time on hovering over pups than 
the VEH+TCB-2 group (both p < 0.047).  
Figure S.2C shows the results of pup licking. Repeated measures ANOVA revealed a main 
effect of group [F(3, 27) = 4.009, p = 0.018], a significant group × test time interaction [F(9, 81) 
= 3.632, p = 0.001], but not a main effect of test time [F(3, 81) = 2.597, p = 0.058]. Post hoc LSD 
tests indicated that the SB242084-(0.6 or 1.0)+TCB-2 groups spent less time on pup licking than 
the VEH+VEH group (both p < 0.008), but there were no significant difference between the 
VEH+TCB-2 and VEH+VEH groups (p = 0.146), and between the two SB242084+TCB-2 and 
VEH+TCB-2 groups (both p > 0.150).  
Figure S.2D shows the results of nest building. TCB-2 decreased amount of time spent on nest 
building, but neither doses of SB242084 were effective in changing the effect of TCB-2. Repeated 
measures ANOVA revealed a main effect of group [F(3, 27) = 5.834, p = 0.003], a main effect of 
test time [F(3, 81) = 54.019, p = 0.000], and a significant group × test time interaction [F(9, 81) = 
7.279, p = 0.000]. Post hoc LSD tests indicated that the VEH+TCB-2, SB242084-(0.6 or 
1.0)+TCB-2 groups spent less time on nest building than the VEH+VEH group (all p < 0.021), but 
there were no significant difference between the two SB242084+TCB-2 and the VEH+TCB-2 
groups (both p > 0.142).  
  
 Figure S.2. Effects of SB242084 (0.6, 1.0 mg/kg) pretreatment on TCB-2 (2.5 mg/kg)’s disruptive 
effect on maternal behavior. Latency of 1st pup retrieval (A), and time spent on hovering over pups 
(B), nursing (C) and nest-building (D) on PPD 4 are presented. SB242084 (0.6, 1.0 mg/kg) was 
injected 10 min before the second VEH and TCB-2 injection. Maternal behavior was tested for 10 
min at 30 min before (baseline), 30 min, 90 min and 150 min after TCB-2 injection. Data in each 
test are expressed as mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 significantly different 
between the VEH+VEH and TCB-2 groups. # p < 0.05, ## p < 0.01 significantly different between 
MK212-(0.5, or 1.0) and VEH+TCB-2 groups. 
Figure S.3A shows the results of the 1st pup retrieval latency. TCB-2 prolonged the 1st pup 
retrieval latency, and MK212 were effective in enhancing the effect of TCB-2. Kruskal-Wallis test 
showed a significant group difference at 30, 90, and 150 min time points (all p <0.001). Mann-
Whitney U test indicated that VEH+TCB-2 and MK212-(0.5, or 1.0)+TCB-2 groups had a longer 
1st pup retrieval latency than the VEH+VEH group (all p <0.001). More importantly, the MK212-
1.0+TCB-2 group actually had longer latency than the VEH+TCB-2 group (p = 0.038) at 30 min 
time point. 
Figure S.3B shows the results of hovering over pups. TCB-2 decreased amount of time spent 
on hovering over pups, but neither doses of MK212 were effective in changing the effect of TCB-
2. Repeated measures ANOVA revealed a main effect of group [F(3, 26) = 9.205, p = 0.000], a 
main effect of test time [F(3, 78) = 13.656, p = 0.000], and a significant group × test time 
interaction [F(9, 78) = 3.464, p = 0.001]. Post hoc LSD tests indicated that the VEH+TCB-2, 
MK212-(0.5, or 1.0)+TCB-2 groups spent less time on hovering over pups than the VEH+VEH 
group (all p < 0.002). There were no significant difference between the MK212-(0.5, or 1.0)+TCB-
2 and VEH+TCB-2 groups (both p > 0.501).  
Figure S.3C shows the results of pup licking. Repeated measures ANOVA revealed a main 
effect of test time [F(3, 78) = 3.797, p = 0.013], a significant group × test time interaction [F(9, 
78) = 3.916, p = 0.000], but not a main effect of group [F(3, 26) = 2.686, p = 0.067]. Post hoc LSD 
tests indicated that the MK212-0.5+TCB-2 group spent less time on pup licking than the 
VEH+VEH group (p = 0.011), but there were no significant difference among the VEH+TCB-2, 
MK212-1.0+TCB-2 and the VEH-VEH groups (both p > 0.057), and between the MK212-(0.5, 
1.0)+TCB-2 and VEH-TCB-2 groups (both p > 0.194).  
Figure S.3D shows the results of nest building. TCB-2 decreased amount of time spent on 
nest building, but neither doses of MK212 were effective in changing the effect of TCB-2. 
Repeated measures ANOVA revealed a main effect of group [F(3, 26) = 10.275, p = 0.000], a 
main effect of test time [F(3, 78) = 26.834, p = 0.000], and a significant group × test time 
interaction [F(9, 78) = 2.976, p = 0.004]. Post hoc LSD tests indicated that the VEH+TCB-2, 
MK212-0.5+TCB-2, and MK212-1.0+TCB-2 groups spent less time on nest building than the 
VEH+VEH group (all p < 0.002), but there were no significant difference between MK212-(0.5 
or 1.0 mg/kg)+TCB-2 and the VEH+TCB-2 groups (both p > 0.484).  
 
 Figure S.3. Effects of MK212 (0.5, 1.0 mg/kg) pretreatment on TCB-2 (2.5 mg/kg)’s disruptive 
effect on maternal behavior. Latency of 1st pup retrieval (A), and time spent on hovering over pups 
(B), nursing (C) and nest-building (D) on PPD 4 are presented. MK212 (0.5, 1.0 mg/kg) was 
injected together with TCB-2. Pup retrieval was tested for 10 min at 30 min before (baseline), 30 
min, 90 min and 150 min after TCB-2 injection. Data in each test is expressed as mean + SEM. * 
p < 0.05, ** p < 0.01, *** p < 0.001 significantly different between the VEH+VEH and TCB-2 
groups. # p < 0.05, ## p < 0.01 significantly different between MK212-(0.5, or 1.0) and 
VEH+TCB-2 groups. 
 3. Experiment 4: neural basis of TCB-2’s effect on maternal behavior: a microinjection study  
Figure S.4 showed that intra-mPOA infusion of TCB-2 had no effect on the latency of the 1st 
pup retrieval (all p > 0.224), the amount of time spent by the mothers on hovering over pups (all p 
> 0.051), pup licking (all p > 0.157), and nest building (all p > 0.08) at both 10 and 60 min time 
points. 
 
Figure S.4. Effects of TCB-2 microinfused into the medial preoptic area (mPOA) on maternal 
behavior throughout the four test days (PPD 4, 6, 8 and 10). Latency of 1st pup retrieval (A), and 
time spent on hovering over pups (B), licking (C) and nest-building (D) in each test is expressed 
as mean + SEM. 
 
In the within-subjects test (Figure S.5), intra-mPFC infusion of TCB-2 prolonged the latency 
of 1st pup retrieval at 4 µg/side at 60 min time point (p = 0.017), but not at 0.1or 0.4 µg/side at 
either 10 or 60 min time points (all ps > 0.16). Similarly, intra-mPFC infusion of TCB-2 decreased 
the amount of time spent by the mothers on hovering over pups at 0.4 or 4 µg/side at 60 min time 
point (p = 0.028 and 0.032, respectively), but not at 10 min point; or at 0.1 µg/side at either 10 or 
60 min time points (all ps > 0.055), although the baseline level of TCB-2 4 was lower than the 
VEH group (p = 0.005). TCB-2 injected into the mPFC also decreased time on nest building at 0.4 
µg/side (p = 0.05) or at 4 µg/side at 10 and 60 min time points (p = 0.008 and 0.037, respectively), 
but not at 0.4 µg on 10 min point or at 0.1 µg on both time points (all ps > 0.084), although the 
baseline level of TCB-2 at 0.4 µg/side was lower than the VEH group (p = 0.048). Intra-mPFC 
infusion of TCB-2 did not affect the time spent on pup licking (all ps > 0.071). 
 Figure S.5. Effects of TCB-2 microinfused into the medial prefrontal cortex (mPFC) on maternal 
behavior throughout the four test days (PPD 4, 6, 8 and 10). Latency of 1st pup retrieval (A), and 
time spent on hovering over pups (B), licking (C) and nest-building (D) in each test is expressed 
as mean + SEM. * p < 0.05, ** p < 0.01 significantly different between the VEH and TCB-2 
groups. 
 
 
In the second batch of rats tested using the between-subjects condition showed that TCB-2 at 
4 µg/side in mPFC also impaired other maternal behaviors (Figure S.6). On PPD 6, it prolonged 
the 1st pup retrieval latency at 30 min (p = 0.003) and 120 min (p = 0.021) on PPD 4, at 30 min (p 
= 0.033) and 120 min (p = 0.002), but not at 30 or 120 min on PPD 8 or 10 (all ps >0.097). It 
decreased amount of time spent by the mothers on hovering over pups at 30 min (p = 0.002) but 
not 120 min (p = 0.752) on PPD 4, at both 30 and 120 min on PPD 8 (p = 0.028 and 0.023, 
respectively), at 30 min (p = 0.003) but not at 120 min (p = 0.201) on PPD 10 (both ps > 0.503). 
It decreased time spent by the mothers on pup licking at 30 min (p = 0.012) but not 120 min (p = 
0.209) on PPD 4, at both 30 and 120 min on PPD 8 (p = 0.003 and 0.02, respectively), at 30 and 
120 min (p = 0.001 and 0.013, respectively) on PPD 10, and no effect was showed on PPD 6 (both 
ps > 0.797). It decreased time spent by the mothers on nest building at 30 min (p = 0.002) but not 
at 120 min (p = 0.257) on PPD 4, at both 30 and 120 min points on PPD 6 (p = 0.001 and 0.000, 
respectively), at 30 and 120 min (p = 0.012 and 0.042, respectively) on PPD 10, and no effect was 
showed on PPD 8 (both ps > 0.05). 
 
 
 
 
  
 
Figure S.6. Effects of TCB-2 microinfused into the medial prefrontal cortex (mPFC) on maternal 
behavior throughout the four test days (PPD 4, 6, 8 and 10). Latency of 1st pup retrieval (A), and 
time spent on hovering over pups (B), licking (C) and nest-building (D) in each test is expressed 
as mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 significantly different between the VEH 
and TCB-2 groups. 
 
